What is the 13F Pro Quality Score for GLUE?

13F Pro ranks Monte Rosa Therapeutics, Inc. (GLUE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View GLUE's current score at https://13fpro.ai/research/GLUE (free sign-up required for the full ranking).

Which hedge funds own the most GLUE stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of GLUE include NEA Management Company,, BlackRock,, TCG Crossover Management,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/GLUE as soon as new 13F filings post.

Where does 13F Pro source GLUE data?

All Monte Rosa Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Monte Rosa Therapeutics, Inc. files with the SEC under CIK 1826457. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is GLUE in?

Monte Rosa Therapeutics, Inc. (GLUE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is GLUE research updated on 13F Pro?

GLUE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Monte Rosa Therapeutics, Inc.(GLUE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1826457 GLUE stock profile & AI dashboard →

13F Pro Quality Score

18.1/100

Rank #2,709 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

1.1/100

Profitability

13.5/100

Balance Sheet

19.5/100

Earnings Quality

30.0/100

Free Cash Flow

14.7/100

Institutional Flow

99.5/100

Revenue Scale

19.8/100

Dilution Risk

12.3/100

GLUE Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Monte Rosa Therapeutics, Inc. (GLUE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GLUE at 18.1/100 on a 32-signal composite quality model, placing it at rank #2,709 of 2,879 stocks — the bottom half of the AI-ranked universe. GLUE scores in the top quartile across institutional flow (99.5). Areas of concern include revenue growth (1.1) and profitability (13.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 12.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Monte Rosa Therapeutics, Inc. reports quarterly revenue of $4.2M, net income of $-44.5M, free cash flow of $-39.2M. Top institutional holders of GLUE by reported 13-F value include NEA Management Company,, BlackRock,, TCG Crossover Management,, based on the most recent SEC filings. GLUE trades on the Nasdaq exchange and files with the SEC under CIK 1826457. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GLUE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Monte Rosa Therapeutics, Inc. directly from SEC EDGAR. Monte Rosa Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 8 and 40 since 2026, currently 18.1 — an improving long-term trajectory across 36 quarterly and live scoring snapshots.

Revenue

Q1 2026

$4.2M

Net Income

Q1 2026

$-44.5M

Free Cash Flow

Q1 2026

$-39.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+63.5% YoY

$123.7MFY 2025

FY20 —FY22 —FY24 $75.6MFY25 $123.7M

Net Income

+46.9% YoY

$-38.6MFY 2025

FY20 $-35.9MFY22 $-108.5MFY24 $-72.7MFY25 $-38.6M

Operating Income

+33.2% YoY

$-54.2MFY 2025

FY20 $-28.0MFY22 $-112.4MFY24 $-81.1MFY25 $-54.2M

Total Assets

+2.3% YoY

$448.7MFY 2025

FY20 $49.4MFY22 $342.4MFY24 $438.7MFY25 $448.7M

Op. Cash Flow

-154.3% YoY

$-22.8MFY 2025

FY20 $-23.1MFY22 $-92.5MFY24 $42.0MFY25 $-22.8M

Metric	FY 2025	FY 2024	FY 2022	FY 2020
Revenue	$123.7M +63.5%	$75.6M	—	—
Net Income	$-38.6M +46.9%	$-72.7M +33.0%	$-108.5M -202.4%	$-35.9M
Operating Income	$-54.2M +33.2%	$-81.1M +27.8%	$-112.4M -301.2%	$-28.0M
Total Assets	$448.7M +2.3%	$438.7M +28.1%	$342.4M +593.4%	$49.4M
Operating Cash Flow	$-22.8M -154.3%	$42.0M +145.4%	$-92.5M -301.1%	$-23.1M

AI Insight: GLUE Financial Trends

A large equity raise in Q1 2026 boosted equity to $522M, but core operating losses of $50M signal the milestone-driven revenue spike in Q4 2024–Q1 2025 has fully unwound.

• Revenue collapsed from a $85M peak in Q1 2025 to just $4M in Q1 2026, reflecting lumpy collaboration milestones rather than recurring commercial sales.

• Operating loss widened to $50M in Q4 2025 and Q1 2026, matching the worst levels seen before the one-time revenue windfall.

• Equity surged from $233M in Q4 2025 to $522M in Q1 2026, indicating a significant capital raise that extended the cash runway.

• Operating cash flow has been deeply negative in three of the last four quarters, averaging roughly $-38M, with Q3 2025's $100M inflow appearing one-time.

⚠ With $50M quarterly operating burn and no debt reported, monitor how long the Q1 2026 equity raise sustains operations before another financing is needed.

⚠ Revenue visibility is near zero at $3–4M per quarter ex-milestones; any new collaboration deal would be a key positive inflection to track.

⚠ Equity grew $289M quarter-over-quarter in Q1 2026 — confirm whether dilution from the raise is offset by pipeline progress updates.

AI Insight: GLUE Ratio Trends

GLUE's profitability spike in Q4 2024–Q1 2025 was fleeting; ROE collapsed from +68.2% in Q1 2025 to -79.2% by Q4 2025.

• ROE swung from -54.0% in Q2 2024 to a peak of +68.2% in Q1 2025, then plunged to -79.2% in Q4 2025.

• ROIC mirrored the reversal: +64.0% in Q1 2025 versus -85.3% in Q4 2025, the worst reading in the dataset.

• TTM ROE of -24.9% and ROIC of -28.4% confirm sustained capital destruction on a trailing twelve-month basis.

⚠ Q4 2024–Q1 2025 positive margins appear one-off; their source warrants scrutiny — likely a milestone payment or collaboration revenue.

⚠ ROA deteriorated to -41.1% in Q4 2025 before partially recovering to -24.2% in Q1 2026 — trend direction unclear.

⚠ D/E data is entirely absent; debt structure and cash runway remain unquantifiable from this dataset alone.

Get alerted when GLUE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Monte Rosa Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of GLUE

NEA Management Company, LLC
$126.5M7,692,298 sh
BlackRock, Inc.
$92.7M5,637,684 sh
TCG Crossover Management, LLC
$76.0M4,622,151 sh
BVF INC/IL
$73.4M4,460,886 sh
BAKER BROS. ADVISORS LP
$71.5M4,345,736 sh
SUVRETTA CAPITAL MANAGEMENT, LLC
$69.5M4,226,809 sh
Vestal Point Capital, LP
$59.3M3,603,465 sh
STATE STREET CORP
$55.2M3,353,980 sh
BRAIDWELL LP
$52.7M3,206,574 sh
Versant Venture Management, LLC
$52.3M3,180,780 sh

Fund	Value	Shares
NEA Management Company, LLC	$126.5M	7,692,298
BlackRock, Inc.	$92.7M	5,637,684
TCG Crossover Management, LLC	$76.0M	4,622,151
BVF INC/IL	$73.4M	4,460,886
BAKER BROS. ADVISORS LP	$71.5M	4,345,736
SUVRETTA CAPITAL MANAGEMENT, LLC	$69.5M	4,226,809
Vestal Point Capital, LP	$59.3M	3,603,465
STATE STREET CORP	$55.2M	3,353,980
BRAIDWELL LP	$52.7M	3,206,574
Versant Venture Management, LLC	$52.3M	3,180,780

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put GLUE on your watchlist

Track score changes the day Monte Rosa Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is GLUE a good stock to buy?

13F Pro's AI-powered analysis of Monte Rosa Therapeutics, Inc. (GLUE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GLUE are available on the GLUE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own GLUE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GLUE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Monte Rosa Therapeutics, Inc.'s investment landscape.